Gilead Sciences (NASDAQ:GILD) Price Target Raised to $148.00 at Leerink Partners

Gilead Sciences (NASDAQ:GILD) had its target price lifted by Leerink Partners from $146.00 to $148.00 in a research report sent to investors on Wednesday morning,MarketScreener reports. Leerink Partners currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on the company. Truist Financial upped their target price on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday. HSBC raised their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Citigroup increased their price target on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Finally, BMO Capital Markets increased their target price on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Twenty-three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $152.50.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $154.98 on Wednesday. Gilead Sciences has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a market cap of $192.28 billion, a price-to-earnings ratio of 22.89, a PEG ratio of 1.22 and a beta of 0.36. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The business’s 50 day simple moving average is $130.27 and its 200 day simple moving average is $122.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 46.68%.

Insider Activity

In other news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director directly owned 1,339 shares in the company, valued at $170,186.90. This represents a 67.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. This trade represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 319,391 shares of company stock worth $44,141,101. 0.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares during the last quarter. State Street Corp grew its holdings in Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the period. Geode Capital Management LLC lifted its holdings in Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $2,617,152,000. Finally, Invesco Ltd. lifted its position in Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after buying an additional 1,618,453 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.